Adagene Inc (ADAG) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN US0053291078
Adagene Inc financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 103,204.00 USD | 7.67 m USD |
| Gross profit | -823,044.00 USD | 7.67 m USD |
| Operating income | -35.95 m USD | -21.44 m USD |
| EBIT | -32.59 m USD | -17.44 m USD |
| Net income | -33.42 m USD | -17.61 m USD |
| Diluted EPS – continuing operations | -0.93 USD | -0.47 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Adagene Inc
Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
More stocks
- Bahvest Resources Bhd (0098.KL)
- FIT Holding Co Ltd (3712.TW)
- Heliad (A7A.DE)
- HURCO COMPANIES INC (HURC)
- Schloss Wachenheim (SWA.DE)
- Woojin (105840.KS)
- 6K Additive Inc (6KA.AX)
- Cheng Fwa Industrial Ltd (5426.TWO)
- Centaurus Metals Ltd (CTM.AX)
- Reyon Pharmaceutical Co Ltd (102460.KS)
- Bright Sheland International Co Ltd (4556.TWO)
- Ever Fortune.AI Co. Ltd. (6841.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.